Keyword Analysis & Research: dostarlimab cpt

gskpro.com

https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Jemperli/pdf/JEMPERLI-PI-MG.PDF

WEBJEMPERLI (dostarlimab-gxly) injection, for intravenous use . Initial U.S. Approval: 2021 -----RECENT MAJOR CHANGES ----- Indications and Usage (1) 7/2023 Dosage and Administration (2.1, 2.2) 7/2023 Warnings and Precautions, Severe and Fatal Immune … File Size: 240KB Page Count: 28

File Size: 240KB

Page Count: 28

DA: 9 PA: 36 MOZ Rank: 22

fda.gov

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf

WEBJEMPERLI (dostarlimab-gxly) injection, for intravenous use including liver and thyroid function, at baseline and periodically during Initial U.S. Approval: 2021 File Size: 460KB Page Count: 23

File Size: 460KB

Page Count: 23

DA: 62 PA: 66 MOZ Rank: 31

fda.gov

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors

DA: 66 PA: 94 MOZ Rank: 95

mednexus.org

https://mednexus.org/doi/10.1016/j.cpt.2023.10.003

WEBOct 19, 2023 · Abstract. Dostarlimab, a programmed death receptor-1 (PD-1)-blocking IgG4 humanized monoclonal antibody, gained accelerated approval from the US Food and …

DA: 31 PA: 59 MOZ Rank: 45

fda.gov

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors

WEBJul 18, 2023 · On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with … cpt

cpt

DA: 2 PA: 5 MOZ Rank: 67

jemperlihcp.com

https://www.jemperlihcp.com/dosing-and-administration/

WEBDosing & Administration | JEMPERLI (dostarlimab-gxly) JEMPERLI + CP Dosing Established in the RUBY Trial 1. Deliver a proven combination up front, then continue with single-agent immunotherapy 1. * 30-minute … cpt

cpt

DA: 74 PA: 53 MOZ Rank: 57

gsk.com

https://us.gsk.com/en-us/media/press-releases/jemperli-plus-chemotherapy-approved-in-us-for-new-indication/

WEBJul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with …

DA: 97 PA: 20 MOZ Rank: 75

ncdhhs.gov

https://medicaid.ncdhhs.gov/blog/2021/07/13/dostarlimab-gxly-injection-jemperli-hcpcs-code-j9999-billing-guidelines

WEBThe ICD-10-CM diagnosis codes required for billing is: C54.1 - Malignant neoplasm of endometrium. Providers must bill with HCPCS code: J9999 - Not otherwise classified, …

DA: 49 PA: 53 MOZ Rank: 17

fda.gov

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dostarlimab-gxly-chemotherapy-endometrial-cancer

WEBJul 31, 2023 · The recommended dostarlimab-gxly dose is 500 mg every 3 weeks for 6 doses with carboplatin and paclitaxel, followed by 1,000 mg monotherapy every 6 weeks … cpt

cpt

DA: 92 PA: 14 MOZ Rank: 31

nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2216334

WEBMar 27, 2023 · Background. Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and … cpt

cpt

DA: 13 PA: 20 MOZ Rank: 85